ClinicalTrials.gg
CompletedNCT03289741Updated May 9, 2025Results posted

A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide

A Phase 4 interventional study of Octreotide and LAR Lanreotide in Neuroendocrine Tumors, sponsored by Memorial Sloan Kettering Cancer Center. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-09.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 218 studies in Neuroendocrine Tumors with a site in United States — 44 open to participants now, 77 under way, 10 of them phase 3. Neuroendocrine Tumors · United States.

Enrollment
76th of 189
51 · median 36
Started
2017
with 21 others
Phase 4
5 of 218
1 open now
Registered
116th of 218
by date
Lead sponsor
9 of 218
Memorial Sloan Kettering Cancer Center

Among the 218 studies in Neuroendocrine Tumors with a site in United States, this one is the 76th largest by enrollment of the 189 interventional ones that give a count, is one of 22 that started in 2017, is one of 5 in phase 4, and was the 116th registered.

Neuroendocrine Tumors

543 studies on the registry are indexed under Neuroendocrine Tumors; 136 are open to participants now.

Browse Neuroendocrine Tumors studies →

Open to participants now

44 of the 218 studies in Neuroendocrine Tumors with a site in United States are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 112 Neuroendocrine Tumors studies recruiting now, 73 (65%) set no upper age limit and 17 (15%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 218 studies in Neuroendocrine Tumors with a site in United States, or all of them as a file.
02

Study summary

This study is being done to evaluate differences in patient experience during treatment with octreotide LAR and lanreotide.

03

Conditions studied

  • Neuroendocrine Tumors

Browse trials for

Keywords

  • Octreotide
  • Lanreotide
  • 17-422
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to provide written for the trial
  • ≥ 18 years of age
  • - or cytologically- confirmed locally advanced or WDNET
  • SSA therapy is recommended by physician for disease management, and has not yet begun
  • performance status of 0, 1, or 2

Exclusion criteria

Exclusion Criteria:

  • Currently participating in a study of an agent
  • Prior chemotherapy, targeted small molecule therapy within 2 weeks prior to study Day 1 or not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent

    *Note: Subjects with ≤ Grade 2 neuropathy or ≤ Grade 2 alopecia are an exception to this criterion and may qualify for the study

  • No concurrent chemotherapy or targeted small molecule therapy
  • If received major surgery, not recovered adequately from the toxicity and/or complications from the intervention prior to starting the study
  • Known additional that is progressing or requires active treatment
  • Active infection requiring systemic therapy
  • Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    Octreotide then Lanreotide

    Each patient on study will receive three injections of intramuscular (IM) octreotide Long Acting Release (LAR). Octreotide LAR for 3 injections followed by lanreotide for 3 injections

    Drug: Octreotide · Drug: LAR Lanreotide · Behavioral: Questionnaires

  • Experimental
    Lanreotide then Octreotide

    Each patient on study will receive three injections of deep subcutaneous (subq) lanreotide. Lanreotide for 3 injections followed by octreotide LAR for 3 injections

    Drug: Octreotide · Drug: LAR Lanreotide · Behavioral: Questionnaires

Interventions

  • Patients will receive three monthly injections every 28 (+/- 3) days. Octreotide LAR for 3 injections followed by lanreotide for 3 injections

  • DrugLAR Lanreotide

    Patients will receive three monthly injections every 28 (+/- 3) days. Lanreotide for 3 injections followed by octreotide LAR for 3 injections

  • BehavioralQuestionnaires

    Baseline questionnaire, Post-treatment questionnaire (after the first 3 injections), Preference questionnaire and Pain Score Diary.

06

What researchers measure

Primary outcomes

  1. Mean Pain Scores at 3 Months

    Patients will rate, on a numeric scale of 0 to 10, with 0 being No pain" to 10 being "Worst pain ever" the pain or discomfort experienced with the SSA injection.

    Time frame: 3 months

07

Results

Posted May 9, 2025

Participant flow

Participant flow — Overall Study
MilestoneOctreotide Then LanreotideLanreotide Then Octreotide
Started2625
Completed2222
Not completed43
Withdrew: Adverse event11
Withdrew: Physician decision22
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryMean Pain Scores at 3 Months

Patients will rate, on a numeric scale of 0 to 10, with 0 being No pain" to 10 being "Worst pain ever" the pain or discomfort experienced with the SSA injection.

Time frame:
3 months
Reported as:
Mean · scores on a scale
Mean Pain Scores at 3 Months
scores on a scaleOctreotide Then LanreotideLanreotide Then Octreotide
Octreotide, first intervention (3 months)2.4 (0 to 10)—
Lanreotide, second intervention (6 months)2.4 (0 to 10)—
Lanreotide, first intervention (3 months)—1.9 (0 to 10)
Octreotide, second intervention (6 months)—1.9 (0 to 10)

Adverse events

Collected over Up to 2 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Octreotide13/51 (25.5%)13/51 (25.5%)0/51 (0%)
Lanreotide8/51 (15.7%)8/51 (15.7%)0/51 (0%)
Most frequent serious events
Most frequent serious events
EventOctreotideLanreotide
Death NOSGeneral disorders13/518/51

Baseline characteristics

Age, Continuous
Age, Continuous(years)Octreotide Then LanreotideLanreotide Then OctreotideTotal
Mean63 (40 to 83)67 (47 to 87)65 (40 to 87)
Sex: Female, Male
Sex: Female, Male(Participants)Octreotide Then LanreotideLanreotide Then OctreotideTotal
Female111526
Male151025
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Octreotide Then LanreotideLanreotide Then OctreotideTotal
Hispanic or Latino112
Not Hispanic or Latino232144
Unknown or Not Reported235
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Octreotide Then LanreotideLanreotide Then OctreotideTotal
American Indian or Alaska Native000
Asian303
Native Hawaiian or Other Pacific Islander000
Black or African American044
White211940
More than one race112
Unknown or Not Reported112
Region of Enrollment
Region of Enrollment(Participants)Octreotide Then LanreotideLanreotide Then OctreotideTotal
United States262551
08

Study locations

7 sites
  • Memorial Sloan Kettering Basking Ridge
    Basking Ridge, New Jersey 07920, United States
  • Memorial Sloan Kettering Monmouth
    Middletown, New Jersey 07748, United States
  • Memorial Sloan Kettering Bergen
    Montvale, New Jersey 07645, United States
  • Memorial Sloan Kettering Commack
    Commack, New York 11725, United States
  • Memorial Sloan Kettering West Harrison
    Harrison, New York 10604, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Memorial Sloan Kettering Nassau
    Uniondale, New York 11553, United States
09

References and documents

Publications

  • Raj N, Cruz E, O'Shaughnessy S, Calderon C, Chou JF, Capanu M, Heffernan O, DeMore A, Punn S, Le T, Hauser H, Saltz L, Reidy-Lagunes D. A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors. JCO Oncol Pract. 2022 Sep;18(9):e1533-e1541. doi: 10.1200/OP.22.00055. Epub 2022 Jun 20. PubMed 35724357 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2017 to primary completion in Apr 2023, 66 months.

Results were first posted in May 2025, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2017
First posted
Sep 21, 2017
StartActual
Sep 19, 2017
Primary completionActual
Apr 10, 2023
CompletionActual
Apr 10, 2023
Results first posted
May 9, 2025
Last update
May 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03289741
Responsible party
Sponsor
First posted
Sep 21, 2017
Start date
Sep 19, 2017
Primary completion
Apr 10, 2023
Completion
Apr 10, 2023
Results posted
May 9, 2025
Last update
May 9, 2025

Study contacts

Nitya Raj, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Octreotide

Start the discussion